Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.W | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Maintenance Dose

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Jun 30, 2022 1:34pm

164 Views

Post# 34794385

RE:RE:RE:RE:RE:RE:RE:RE:RE:Maintenance Dose

Hi Pandora - yes, the 41 patients mentioned in Tuesday's news release includes all of the patients who have been treated in the phase 2 trial so far.

Pandora wrote:
So the first 8 of the first 12 are effectively not countable for study purposes - in our amateur look at things? Yet they are included?
Presumably Study regulations do not allow deleting any patients from the data base regardless of the circumstances.

When reference is made in Study II data to 38 patients - or now 41 patients, those 8 are still included?

They have not reverted numbers back to 30 and 33 by excluding those first 8? And the data table does not make it easy(simple) to differentiate (or cleanse) the numbers?